Mentara Bio Inc.
PrivateLast Round
Series B
May 1, 2024
Total Funding Raised
$10.2M
Company Overview
Mentara Bio Inc. is a biotechnology company that develops innovative therapies for neurological disorders, including epilepsy and Dravet syndrome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mentara Bio Inc. Comparables
Compare Mentara Bio Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Engrail Therapeutics | 78% | |
| Praxis Precision Medicines, Inc. | 75% | |
| H. Lundbeck A/S | 74% | |
Mentara Bio Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 1, 2024 | ||||
| Series A | Mar 6, 2023 | ||||
| Grant | Feb 15, 2022 | ||||
| Series A | Dec 13, 2021 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 3, 2026
Monthly visitors grew 122% MoM, reaching 1.3K.
- Nov 8, 2025
Monthly visitors increased 35% MoM.
Mentara Bio Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Mentara Bio Inc.'s valuation, stock price, and market status.